; (ii) the projected need for COVID–19 in vitro diagnostic products (as defined in section 809.3 of title 21, Code of Federal Regulations (or successor regulations)) during the period of the grant; (iii) the percentage of COVID–19 cases per 10,000 persons as of the date of submission of the application for the grant; (iv) the COVID–19 case growth rate; and (v) the projected number of COVID–19 cases during the period of the grant; and (B) an additional increment for States that have a plan to increase the percentage of the population that will be tested. (c) Required uses of funds Amounts made available to a grantee pursuant to subsection (a) shall be used for the following activities: (1) Costs, including wages and benefits, including health care benefits, as appropriate, related to the recruiting and hiring of individuals— (A) to serve as case investigators, contact tracers, and social support specialists described in paragraphs (1), (2), and (3), respectively, of section 2(c); and (B) employed by— (i) the State or local government involved; or (ii) a nonprofit organization with demonstrated expertise in implementing public health programs. (2) Supplies necessary for grantees to implement the strategy established under section 2, including any supplies, equipment, or technology for individuals serving as case investigators, contact tracers, or social support specialists. (3) Administrative costs and activities necessary for grantees to implement the strategy established under section 2. (4) Development of partnerships with State and local workforce development systems as defined in section 3 of the Workforce Innovation and Opportunity Act ( 29 U.S.C. 3102 ) to provide training and supportive service for individuals serving as case investigators, contact tracers, or social support specialists. (5) Reporting to the Centers for Disease Control and Prevention on— (A) implementation of the strategy established under section 2